Vashisht Gopal Yennu Nanda
15 works · 190 citations · h-index 4
Top works
- Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment
- PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery
- Melanoma and immunotherapy bridge 2015
- RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma
- Abstract 5396: Interferon-α receptor dependent and independent inhibition of type I interferon production in plasmacytoid dendritic cells from mice and melanoma patients
- Abstract LB-228: Resistance to BRAF inhibition in BRAF V600E colorectal cancer is associated with PI3K/AKT activation and hypermethylation
- Abstract PR06: The glutaminase inhibitor CB-839 potentiates antimelanoma activity of standard-of-care targeted therapies and immunotherapies
- Abstract LB-367: [18F]FAZA PET imaging reveals precise pharmacodynamics in vivo of the novel chemotherapeutic IACS-010759
- Downregulation of Breast Cancer Gene Expression by Small Molecule Drugs
- Expanding the Tumor Mutation Burden in Mouse Melanoma Cells
- Role of Melanin in Oncogenesis
- Abstract A52: Overcoming mitochondrial oxidative phosphorylation-mediated resistance to targeted therapies in melanoma
- Abstract A71: Basal- and treatment-induced activation of the PI3K-AKT pathway are critical determinants of the efficacy of the MEK inhibitor AZD6244 (ARRY-142886) in melanoma
- RMEL3, a long noncoding RNA, induces tumor malignancy through the MAPK and PI3K pathways in BRAFV600E melanomas